Bioatla, Inc. · NASDAQ:BCAB
Bioatla — Needham & Co Annual Healthcare Conference 2022
19 slides from Bioatla's conference presentation, Apr 11, 2022
Slide 1: Transforming Cancer Therapy
Exhibit 99.1 TRANSFORMING CANCER THERAPY April 2022 Needham & Co Annual Healthcare Conference 1 `
Slide 2: Important Notices & Disclaimers
Important Notices & Disclaimers This presentation (the “Presentation”) by BioAtla, Inc. (“we”, “us”, “our”, “BioAtla”, or the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial
Slide 3: BioAtla is a clinical-stage biotech company transforming cancer therapy with CABs
© BioAtla is a clinical-stage biotech company focused on transforming cancer therapy with Conditionally Active Biologics (CABs) THE COMPANY TECHNOLOGY CLINICAL & TEAM FINANCE & INFRASTRUCTURE Proprietary CAB technology that Broad clinical and development Building on successful 2020 IPO, conditionall
Slide 4: Tumor cell acidity enables selective, reversible CAB binding
Tumor cell acidity enables selective, reversible CAB binding via the novel TM* physiological-occurring PaCS molecule mechanism THE TECHNOLOGY In Acidic Cancer Cell Membranes In Alkaline Healthy Cell Membranes… BioAtla CAB antibodies In normal tissue (+) charged In the acidic TME the PaCS selectively
Slide 5: Leveraging advantages of CAB technology
Leveraging advantages of CAB technology Anticipated advantages of CAB technology Examples of CAB technology’s broad application Improved safety and efficacy Targeting CTLA4 1 (BA3071 – Naked Antibody) Enhanced pharmacologic properties Targeting EpCAM x CD3 2 (BA3182 – Bispecific) Develop therapeutic
Slide 6: BA3071 (CAB-CTLA4): best-in-class and potential for disruption of the I/O market
BA3071 (CAB-CTLA4): best-in-class and potential for disruption of the I/O Market Nivolumimab Nivolumimab (PD-1) + Research demonstrates challenges and Clinical Endpoint (PD-1) Ipilumimab (CTLA4) opportunity in combining two Immune Progression Free Survival 6.9 months 11.5 months Checkpoint Inhibitor
Slide 7: CAB-EpCAM x CAB-CD3 bispecific exhibits comparable tumor shrinkage with superior safety
CAB-EpCAM x CAB-CD3 bispecific antibody exhibits comparable tumor shrinkage with superior safety profile CAB EpCAM x CAB CD3 bispecific Dual selection results in high selectivity demonstrates efficient tumor shrinkage Tumor Cell Target CAB-EpCAM CAB-CD3 T Cell Target Bispecific Safety Results (Non-G
Slide 8: Robust pipeline of differentiated CAB assets
Robust pipeline of differentiated CAB assets designed to deliver near-, mid- and long-term value IND Enabling Phase 1 Phase 2 Program Target Lead Indications Pre-Clinical Clinical BA3011 ✓ STS & Bone Sarcoma ✓ NSCLC (Mono & Combo w/ PD-1) Mecbotamab Vedotin AXL ✓ Ovarian Cancer* ✓ NSCLC BA3021 ✓ Mel
Slide 9: Strong execution and compounding momentum through 2021
Strong execution and compounding momentum through 2021 2021 LOOKBACK Initiated four Phase 2 Entered into clinical potentially collaboration with BMS to Secured $75m registration-enabling evaluate two CAB-ADCs in through private ® studies across two combination with Opdivo placement different assets
Slide 10: Four potentially registration-enabling Phase 2 trials ongoing
Four potentially registration-enabling Phase 2 trials ongoing with lead CAB-ADCs, Mecbotamab Vedotin & Ozuriftamab Vedotin Trial Status (Feb. ‘22) # PHASE 2 Sarcoma (STS & Bone) 26 sites activated Ongoing mono & combo w/ PD-1; AXL TmPS*≥50 & ≥70 70 pts fully enrolled rd 3 Line (n=200-275) Mecbo – BA
Slide 11: Significant opportunity to fill treatment void in sarcomas
Significant opportunity to fill treatment void in sarcomas Mecbo – BA3011 SARCOMA Unmet Need for Sarcomas Large and Under-Appreciated ✓ No targeted therapies available for most soft tissue Commercial Opportunity sarcoma ✓ Bone sarcomas have no approved therapies after failure of frontline regimens ✓
Slide 12: Encouraging Phase 1 results with Mecbotamab Vedotin in refractory sarcoma
Encouraging Phase I results with Mecbotamab Vedotin in refractory sarcoma Mecbo – BA3011 PHASE 1 - SARCOMA Confirmed TmPS* ≥70; 1.8mg/kg Q3W or 2Q3W Evaluable Patients in Phase 1 at All Doses High TmPS ≥70 AXL+ 100 Low TmPS ≤70 or Not Evaluable $ TmPS=90 1.8mg/kg 80 Confirmed Partial Response (PR) d
Slide 13: Predefined Interim Analysis: Decision Tree
Predefined Interim Analysis: Decision Tree Mecbo – BA3011 PHASE 2 - SARCOMA ~10 patients w TmPS>=70 LMS Syn ~10 patients w TmPS>=70 STS Lipo For each Subgroup ~10 patients w TmPS>=70 up to 10 patients Others Monotherapy ~10 patients w TmPS>=70 No Go if 0 CR/PR and PFR12 week < 40% Osteo ~10 patients
Slide 14: Preliminary observations from Phase 2 sarcoma study with Mecbotamab Vedotin
Preliminary observations from Phase 2 sarcoma study with Mecbotamab Vedotin Mecbo – BA3011 PHASE 2 - SARCOMA • Study enrolling as per plan with initial interim cohort of ~70 pts enrolled at EOY • Reported good clinical activity in advanced refractory sarcoma population to date • Several cohorts alre
Slide 15: Complete response in ROR2+ melanoma patient and partial response in HNC patient
Complete response in 1/1 ROR2+ patient in stage IV multi-refractory melanoma and partial response in 1/1 ROR2+ patient in head and neck squamous cell cancer (HNC) Ozurif – BA3021 Phase 1 - MELANOMA Two evaluable metastatic melanoma patients enrolled in Phase 1 trial 100 0.6 mg/kg (d1) 80 3.0 mg/kg (
Slide 16: Encouraging Phase 1 results in NSCLC refractory patients
Encouraging Phase I results in NSCLC refractory patients Phase 1 - NSCLC Mecbo – BA3011 Ozurif – BA3021 Response at Variable Dosing Response at Variable Dosing 30% ROR2 + ROR2 – ROR2 + Not ROR2 + ROR2 + (**TmPS=100) (**TmPS=0) (**TmPS=45) Evaluable (**TmPS=95) (**TmPS=70) 1.2mg/kg d1,8 3mg/kg d1 3.3
Slide 17: Promising safety and tolerability profile emerging
Promising safety and tolerability profile emerging PHASE 1 AEs for all doses CAB AXL-ADC Mecbo – BA3011 (all patients n=64) Overview Grade 1-2 (26%) ▪ AEs consistent with MMAE-based toxicity, including: Constipation o Reversible myelosuppression Grade 3 (3%) o Transient liver enzyme elevation Periph
Slide 18: Many value-creating milestones in 2022
Many value-creating milestones in 2022 Key Clinical Updates Mecbotamab Vedotin (BA3011) Mecbotamab Vedotin (BA3011) NSCLC Ozuriftamab Vedotin (BA3021) Sarcoma Phase 2 Interim Update Phase 2 Interim Analysis (1H 2022); NSCLC and Melanoma Phase 2 (1Q earnings call – May 4, 2022) Interim Update (2Q ear
Slide 19: 2022 BioAtla corporate priorities
2022 BioAtla corporate priorities Execute on clinical programs Create long-term sustainable value Create long-term sustainable value Build core commercial capabilities 19
BioAtla — Needham & Co Annual Healthcare Conference 2022 on 6ix